Pacific Edge reviews US pricing for new Cxbladder test, trading halted

Pacific Edge reviews US pricing for new Cxbladder test, trading halted
Pacific Edge says Cxbladder Triage Plus delivers “significant performance improvements” compared to its existing tests. (Image: Pacific Edge)
Rebecca Howard
Pacific Edge has been placed on a trade halt while it reviews draft gapfill or reimbursement rates for its new Cxbladder Triage Plus test from the US Centres for Medicare and Medicaid Services.“[It said it's] reviewing the prices and the associated documentation and needs time to assess the implications of them, consult with its advisers and industry partners, and prepare an announcement that provides context to investors.”Gapfill prices are proposed reimbursement rates for new or unpriced clinical diagnostic laboratory tests.Th...

More Markets

Anna Scott joining Mercer
Markets

Anna Scott joining Mercer

Former Smart boss will replace current Mercer chief executive Martin Lewington.

Solar still on the rise, Ecotricity says
Markets

Solar still on the rise, Ecotricity says

Commercial solar generation is up almost 300%.

Expectations of rate cuts boost NZ sharemarket in light trade
Markets Market close

Expectations of rate cuts boost NZ sharemarket in light trade

There were 89 rises and 48 falls on the main board.

Jamie Gray 02 Jul 2025
Smart CEO Anna Scott resigns
Markets

Smart CEO Anna Scott resigns

Anna Scott will take up her new role on October 1.

Staff reporters 02 Jul 2025